Although the difference of CR‐1 between lung cancer patients and controls was more significant than that of VEGF, the considerable overlaps and numerical discrepancy between the two groups weakened its practicability as a clinical marker, and ROC analysis showed that it did not have a strong ability to distinguish. The gene discussed is VEGFA; the disease is lung carcinoma.